‘The Rheumatoid Arthritis Drugs Market Generated $12.7bn in 2010′ Says visiongain Report

LONDON, September 8, 2011 -

www.visiongain.com/Report/679/Rheumatoid-Arthritis-World-Drug-Market-2011-2021

A new report by visiongain, a London-based business information company, predicts that world revenues for rheumatoid arthritis drugs will rise strongly between 2011 and 2021. This market will grow to reach $17.3bn in 2015. The rheumatoid arthritis drugs market generated $12.7bn in 2010, according to Rheumatoid Arthritis: World Drug Market 2011-2021, published in September 2011.

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which skeletal joints become inflamed, causing pain, swelling and stiffness. RA can affect a person’s ability to carry out everyday tasks. It is not known why rheumatoid arthritis develops, and there is no cure. Understanding of the disease has improved, however, and there are treatments that ease the pain and other symptoms, managing the disease.

Diya Lahiri, pharmaceutical industry analyst, said: “The world rheumatoid arthritis treatments market will benefit from the entry of new drugs this decade. There are prominent needs in the RA market, the most important being the development of drugs that are truly disease modifying rather than merely symptom managing. R&D efforts will help develop novel treatments that will not only benefit patients but also help researchers understand rheumatoid arthritis better.”

Visiongain forecasts that the rheumatoid arthritis drug market will expand steadily to 2021. The future of the market is promising, with increasing demand for novel treatments such as biological drugs. The prospect of newer, more-effective drugs for RA, such as anti-TNF agents, will help this market to grow further. This new study adds to visiongain’s wide range of analytical reports in healthcare and other industry areas.

To view sample pages please click on:

www.visiongain.com/Report/679/Rheumatoid-Arthritis-World-Drug-Market-2011-2021

For an exec summary please email Sara Peerun

Email: sara.peerun@visiongainglobal.com
Tel: +44(0)207-3366100
Web: www.visiongain.com

Table of Contents

1. Executive Summary
1.1 World Rheumatoid Arthritis Treatments Market Outlook
1.2 Aims Scope and Format of the Report
1.3 Research and Analysis Methods
1.4 Chapter Outlines

2. Introduction to Rheumatoid Arthritis
2.1 What is Rheumatoid Arthritis?
2.2 Understanding Joints
2.3 What Causes Rheumatoid Arthritis?
2.3.1 Overactive Immune System: The Immune Response and Inflammation Process
2.3.2 Genetic Factors
2.3.3 Environmental Triggers
2.4 Diagnosis of Rheumatoid Arthritis
2.4.1 Radiographic Features of Rheumatoid Arthritis
2.4.2 Blood Tests
2.4.3 Disorders with Similar Symptoms
2.5 Disease Risk Factors
2.6 Managing Rheumatoid Arthritis
2.6.1 Main Treatments Offered
2.6.2 Other Treatments Offered
2.6.3 Diet and Complementary Therapies
2.6.4 Surgical Options
2.6.5 Monitoring Disease Progression
2.7 Economic Costs of Rheumatoid Arthritis
2.8 World Prevalence of Rheumatoid Arthritis
2.9 Uncertainty on the Incidence of Rheumatoid Arthritis

3. Treatments for Rheumatoid Arthritis
3.1 What Drugs Are Used to Treat RA?
3.2 Pain Relieving Drugs
3.2.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
3.2.2 Side-Effects of NSAIDs
3.3 Corticosteroids
3.4 Disease Modifying Anti-Rheumatic Drugs (DMARDs)
3.4.1 Methotrexate
3.4.2 Biologics
3.4.3 Hydroxychloroquine and Sulfasalazine
3.4.4 Minocycline
3.4.5 Leflunomide
3.4.6 Cyclosporine
3.4.7 Azathioprine
3.5 Biologics for Rheumatoid Arthritis Treatment
3.5.1 What is Tumour Necrosis Factor?
3.5.2 Side-Effects of Biologics
3.5.3 Combining Biologics with DMARDs
3.6 Key Treatments in the RA Drug Market

4. The Global Rheumatoid Arthritis Drug Market, 2011-2021
4.1 The Global Rheumatoid Arthritis Market, 2011-2021
4.2 Non-Biologics for RA
4.2.1 NSAIDs: Market Forecast, 2011-2021
4.2.2 Other Non-Biologics for RA: Market Forecast, 2011-2021
4.3 Biologics for RA: Market Forecast 2011-2021
4.3.1True Contribution of Biologics in the RA Market
4.4 Summary of the Market

5. Main Drugs in the Rheumatoid Arthritis Market, 2011-2021
5.1 Non Steroidal Anti-Inflammatory Drugs (NSAIDs)
5.1.1 Celebrex (Pfizer): Market Forecast, 2011-2021
5.1.1.1 Development of Celebrex
5.1.2 Arcoxia (Merck and Co.): Market Forecast, 2011-2021
5.1.2.1 Development of Arcoxia
5.2 Biologics for RA Treatments
5.2.1 Humira (Abbott Laboratories): Market Forecast, 2011-2021
5.2.1.1 Long Term Prospects for Humira
5.2.2 Remicade (Johnson and Johnson): Market Forecast, 2011-2021
5.2.2.1 Long Term Prospects for Remicade
5.2.3 Enbrel (Amgen; Pfizer; Takeda): Market Forecast, 2011-2021
5.2.3.1 Amgen Continues to Benefit from Enbrel Sales
5.2.3.2 Enbrel Sales Will Show an Initial Increase
5.2.3.3 Study Eases Fears of TNF Blocker Cancer Risk
5.2.3.4 New Enbrel Delivery System
5.2.3.5 Sales of Enbrel Will Eventually Decline
5.2.3.6 Enbrel Faces Competition from Several Other Biotech Drugs
5.2.4 MabThera (Rituxan in the US - Roche; Biogen Idec): Market Forecast, 2011-2021
5.2.4.1MabThera: Leading Biologic for RA
5.2.5 Orencia (Bristol-Myers Squibb): Market Forecast, 2011-2021
5.2.5.1 Orencia: New Biologic for RA
5.2.6 Actemra (Roche): Market Forecast, 2011-2021
5.2.6.1 Actemra Will Achieve Growth
5.2.7 Cimzia (UCB): Market Forecast, 2011-2021
5.2.7.1 Cimzia: Forecast and Analysis, 2011-2021
5.2.8 Kineret (Biovitrium): Future Prospects
5.2.9 Simponi (Johnson and Johnson): Future Prospects

6. R&D Pipeline for Rheumatoid Arthritis Drugs, 2011
6.1 R&D Pipeline: NSAIDs for Rheumatoid Arthritis, 2011
6.1.1 Famotidine + Ibuprofen (Horizon)
6.1.2 Ibuprofen-PC (PLx Pharma)
6.1.3 Apricoxib (Tragara; Daiichi Sankyo)
6.1.4 CEP 33222 (Cephalon; Acusphere)
6.2 R&D Pipeline: Corticosteroids for Rheumatoid Arthritis, 2011
6.2.1 Lodotra (Horizon; SkyePharma)
6.3 R&D Pipeline: Biologics to Treat Rheumatoid Arthritis, 2011
6.3.1 Denosumab (Amgen)
6.3.2 Fostamatinib (AstraZeneca)
6.3.3 Tofacitinib (Pfizer)
6.3.4 Ofatumumab (Genmab; GSK)
6.3.5 Masitinib (AB Science)
6.3.6 Belimumab (GSK; Human Genome Sciences)
6.3.7 Canakinumab (Novartis)
6.3.8 Baminercept Alfa (Biogen Idec)
6.3.9 Ocrelizumab (Roche)
6.3.10 Sarilumab (Regeneron; Sanofi)
6.3.11 dnaJP1 (Adeona)
6.3.12 T-5224 (Roche; Toyoma Chemicals)
6.3.13 Anti- BAFF Monoclonal Antibody (Eli Lilly)
6.3.14 Olokizumab (UCB)
6.3.15 Anti-IL-17 Monoclonal Antibody (Eli Lilly)
6.3.16 JAK1/JAK2 Inhibitor (Eli Lilly)
6.3.17 Sirukumab (Johnson and Johnson)
6.3.18 INCB018424 (Incyte Corporation)
6.3.19 ALD 518 (Bristol Myers Squibb; Alder Biopharmaceuticals)
6.3.20 GSK3152314A (GlaxoSmithKline)
6.3.21 RPI-MN (ReceptoPharm)
6.3.22 MT203 (Nycomed)

7. Leading National Markets for Rheumatoid Arthritis Treatments, 2011-2021
7.1 Leading National Markets for Rheumatoid Arthritis, 2010-2021
7.2 The US Rheumatoid Arthritis Market, 2011-2021
7.3 The Japanese Rheumatoid Arthritis Market, 2011-2021
7.4 The Leading European Markets for Rheumatoid Arthritis Treatments, 2011-2021
7.5 Rheumatoid Arthritis Drug Market in Emerging Economies, 2011-2021
7.5.1 The Chinese Rheumatoid Arthritis Market, 2011-2021
7.5.2 The Indian Rheumatoid Arthritis Market, 2011-2021
7.6 Rheumatoid Arthritis Treatments in the Rest of the World, 2011-2021
7.7 Summary of National Market Forecasts

8. Leading Companies in the Rheumatoid Arthritis Drug Market, 2011
8.1 Introduction
8.2 Roche
8.3 Abbott Laboratories
8.4 Amgen
8.5 Johnson & Johnson
8.6 Biogen Idec

9. Drivers and Restraints in the Rheumatoid Arthritis Drug Market
9.1 SWOT Analysis of the RA Drug Market
9.2 Commercial Drivers in the RA Drug Market
9.2.1 The Biological Drug Market for RA is Well-Established
9.2.2 New Product Development Will Drive the RA Market
9.2.3 Rising Prevalence of RA Will Enhance Market Growth
9.2.4 Small Molecules Will Have a Positive Impact on RA Treatments
9.2.5 Revised Treatment Classification Criteria Will Make Diagnosis Easier
9.3 Commercial Restraints in the RA Drug Market
9.3.1 Biological Drugs - Too Costly in Most Countries?
9.3.2 The Biological Drug Industry - Insufficiently Dynamic?
9.3.3 Unmet Clinical Needs in Rheumatoid Arthritis Treatment Will Slow Growth
9.3.4 Biosimilar Competition May Restrain the RA Market for Biologics
9.3.5 Side-Effects and Costly Treatments
9.3.6 Inadequate Reimbursement for Biologics Will Hamper RA Market Growth
9.4 Concluding Remarks

10. Research Interviews
10.1 Interview 1: Dr Yusuf Yazici, MD, Assistant Professor, Department of Medicine-Rheumatology and Hospital for Joint Diseases and Medicine, New York University
10.1.1 Opinion on the Key Unmet Needs for RA Treatments
10.1.2 Opinions on Current Treatments
10.1.3 Views on Abatacept: New Biologic for RA
10.1.4 Key Challenges: Development and Uptake of Abatacept
10.1.5 Views on Cimzia
10.1.6 Treatments in the R&D Pipeline
10.1.7 Views on the Prevalence of RA
10.2 Interview 2: A Professor Working in Rheumatology
10.2.1 Views on the Prevalence of RA
10.2.2 Views on Anti-TNF Therapies for RA
10.2.3 Opinion on Biosimilars
10.2.4 Key Challenges in the Market
10.2.5 Key Treatment Goals

11. Conclusions
11.1 The RA Market - Revenue Growth
11.2 Non-Biologic Treatments
11.3 Biologic Treatments
11.4 Improvements Needed in RA Treatments
11.5 Future Rheumatoid Arthritis Treatments: R&D Efforts Promising
11.6 The RA Treatments Sector: Looking into the Future Confidently

Notes for Editors

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100

.